MENU
+Compare
TGTX
Stock ticker: NASDAQ
AS OF
Apr 24, 03:30 PM (EDT)
Price
$40.71
Change
+$1.22 (+3.09%)
Capitalization
6.2B

TGTX stock forecast, quote, news & analysis

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases... Show more

Industry: #Biotechnology
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for TGTX with price predictions
Apr 22, 2025

TGTX in +6.32% Uptrend, rising for three consecutive days on April 15, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TGTX advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on TGTX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 221 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TGTX moved out of overbought territory on March 26, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.933) is normal, around the industry mean (13.917). P/E Ratio (263.267) is within average values for comparable stocks, (62.940). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.781). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (19.231) is also within normal values, averaging (251.270).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 31.65 to 266.85B. NONOF holds the highest valuation in this group at 266.85B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -13%. TVRD experienced the highest price growth at 266%, while SCPX experienced the biggest fall at -69%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was 118%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 72
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3020 Carrington Mill boulevard
Phone
+1 212 554-4484
Employees
264
Web
https://www.tgtherapeutics.com